ME 23andMe Holding Co. Forward P/E Multiple

Corporate company logo of 23andMe Inc. (ME)

The potential of 23andMe Holding Co. (ME) is based on the commercialization of biodata through pharma partnerships and the demand for DNA tests. The projected valuation based on the company's P/E ratio visualizes these expectations, with the metric holding around 0.00. However, the current chart is clouded by a critical crisis: cyberattacks, a collapse in subscriptions, and the threat of bankruptcy create extreme risks of the shares being delisted from the exchange.

Market Cap to Projected Earnings: 23andMe (ME) for 07/04/2022 - 04/05/2025

Analytical breakdowns for 23andMe Holding Co.

- stock value and consensus price forecast:
Summary company analytics:23andMe Holding Co.
Brand item of 23andMe Holding Co.

The forward P/E ratio relates the current share price to expected earnings, allowing for an assessment of the premium paid for the business's future income. By analyzing changes in the forward price-to-earnings multiple of 23andMe Holding Co. (ME), an investor can observe the market's reaction to operational reports, which in the case of 23andMe Holding Co. (ME) reflects the critical risk of bankruptcy and delisting amid the collapse of its subscription model and the aftermath of cyberattacks.

Who 23andMe Holding Co. competes with

Forward P/E Multiple A|DGX - Projected Price to Earnings Ratio|Illumina Inc - Projected Price to Earnings|exactsciences.com (EXAS) - Projected Price to Earnings Ratio|RVTY - Future Price to Earnings|Market Cap to Projected Earnings Bio-Rad Laboratories, Inc. BIO|NNNN: Forward P/E Multiple|SHC - Market Cap to Projected Earnings|Future Price to Earnings quidel.com|Projected Price to Earnings Ratio opko.com OPK|Forward P/E Multiple CDNA|Projected Price to Earnings Maravai LifeSciences Holdings, Inc. MRVI|Fulgent Genetics Inc - Projected Price to Earnings|Forward P/E Multiple Standard BioTools Corp LAB|CTKB: Projected Price to Earnings|OSUR - Forward P/E Multiple|XGN: Forward P/E Multiple|MDxHealth - Future Price to Earnings Multiple|LUCD (Lucid Diagnostics Inc.) - Forward P/E Multiple|PRE (Prenetics Global) - Market Cap to Future Earnings Ratio|Forward P/E Multiple IMDX|Market Cap to Future Earnings Ratio TRIB|Future Price to Earnings ProPhase Labs Inc PRPH|Market Cap to Projected Earnings Ainos Inc (AIMD)|CODX - Future Price to Earnings|Projected Price to Earnings Ratio Heart Test Labs|BMRA: Forward P/E Multiple|CDIO - Market Cap to Projected Earnings|Projected Price to Earnings ONCO|Future Price to Earnings VRAX|Forward P/E Multiple BJDX|Aspira Women's Health Inc - Price to Future Earnings Ratio|Forward P/E Multiple AXDX (Accelerate Diagnostics, Inc.)|Market Cap to Projected Earnings Centogene N.V. (CNTG)|Enzo Biochem Inc. - Forward P/E Multiple|FRES: Future Price to Earnings|gtglabs.com (GENE) - Future Price to Earnings|Price to Future Earnings Ratio PMD